Meeting
2023 ASCO Breakthrough
Impact of pathological response and recurrence pattern on the survival of patients who develop recurrence from neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma (ESCC).
Authors
Chien Huai Chuang
National Taiwan University Cancer Center, Taipei City, Taiwan
Chien Huai Chuang , Jhe-Cyuan Guo , Ta-Chen Huang , Tsung-Che Wu , Chih-Hung Hsu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Gastrointestinal Cancer,Gynecologic Cancer,Head and Neck Cancer,Quality of Care,Genetics/Genomics/Multiomics,Healthcare Equity and Access to Care,Healthtech Innovations,Models of Care and Care Delivery,Population Health,Viral-Mediated Malignancies
Sub Track
Multimodality Treatments
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 49)
DOI
10.1200/GO.2023.9.Supplement_1.49
Abstract #
49
Poster Bd #
C6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Tislelizumab plus chemotherapy as induction treatment followed by chemoradiotherapy or surgery in locally advanced hypopharyngeal squamous cell carcinoma: A single-arm, phase II trial.
First Author: Lin Gui
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Short-term safety of adjuvant nivolumab therapy after neoadjuvant docetaxel plus cisplatin and 5-FU therapy for locally advanced esophageal squamous cell carcinoma.
First Author: Toshiharu Hirose
Poster
2017 ASCO Annual Meeting
A phase II study of early FDG-PET evaluation after one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy: Final report.
First Author: Ta-Chen Huang
Poster
2014 Gastrointestinal Cancers Symposium
A phase II study of weekly nab-paclitaxel in combination with cisplatin as neoadjuvant chemotherapy in patients (pts) with locally advanced esophageal squamous cell carcinoma (SCC).
First Author: Fan Yun